利拉鲁肽治疗2型糖尿病合并轻中度慢性肾脏病有效性和安全性分析.docVIP

利拉鲁肽治疗2型糖尿病合并轻中度慢性肾脏病有效性和安全性分析 　　[摘要]目的 探讨利拉鲁肽治疗2型糖尿病（T2DM）合并轻中度慢性肾脏病（CKD）的临床效果与安全性。方法 选择2014年6月～2015年6月我院64例T2DM合并轻中度CKD患者，按随机数字表法将其分为2组，每组32例。对照组予以常规降糖药治疗，治疗组在对照组的基础上联合利拉鲁肽治疗，比较两组治疗24周后的治疗效果和不良反应。结果 治疗24周后，治疗组和对照组分别有2例和1例患者失访，两组患者空腹血糖（FBG）、糖化血红蛋白（HbA1c）、体质量指数（BMI）均较治疗前显著降低，空腹胰岛素（FINS）较治疗前均显著升高，差异有统计学意义（P0.05）。两组各类药物相关不良反应发生率比较，差异无统计学意义（均P0.05）。结论 利拉鲁肽联合常规降糖药治疗T2DM合并轻中度CKD可有效降糖且安全耐受，对患者肾功能、血压、血脂等无明显影响。 　　[关键词]利拉鲁肽；2型糖尿病；慢性肾脏病；不良反应 　　[中图分类号] R587.1 [文献标识码] A [文章编号] 1674-4721（2016）10（c）-0131-03 　　[Abstract]Objective To investigate the clinical efficacy and safety of Liraglutidein in treatment of patients with type 2 diabetes mellitus（T2DM） and mild to moderate chronic kidney disease （CKD）.Methods 64 patients with T2DM and mild to moderate CKD in our hospital from June 2014 to June 2015 were randomly divided into 2 groups according to the random number table method，32 cases in each group.All patients received regular treatment，and treatment group received Liraglutidein addition to the regular treatment.The treatment efficacy and safety at following up of 24 weeks between two groups were compared.Results Two patients lost in treatment group and 1 in control group at the end of following up.At 24 weeks，fasting blood glucose （FBG），hemoglobin A1c （HbA1c）and body mass index（BMI）significantly decreased， and fasting insulin （FINS） significantly increased than before therapy in both treatment and control group （all P0.05）.There was no significant difference in the incidence of adverse drug reactions between the two groups （all P0.05）.Conclusion Liraglutide can be considered as an effective and safe agent for glucose lowering and weight loss in patients with T2DM and mild to moderate CKD.However，Liraglutide has no influence on kidney function，blood pressure and blood lipid. 　　[Key words]Liraglutide；Type 2 diabetes mellitus；Renal disease；Adverse reactions 　　2型糖尿病（T2DM）是慢性肾脏病变（CKD）的重要危险因素，20%～40%的T2DM将进展为糖尿病肾病，而糖尿病肾病是导致终末期肾病的主要原因[1-3]。降糖药物在不同程度肾损伤患者中的安全性和有效性研究证据有限，因降糖药物在不